Management of bleeding emergencies: When to use recombinant activated Factor VII

    Research output: Contribution to journalReview article

    5 Scopus citations

    Abstract

    Recombinant activated Factor VII (rVIIa) was originally released as a clotting factor, with use limited to a select group of patients who had few other treatment options. Due to the apparent ability of rVIIa to stop bleeding, no matter what the underlying cause, there is great interest in use of rVIIa in a wide range of bleeding patients. This article discusses rVIIa and its uses in a variety of patients, especially liver disease and trauma patients, and makes suggestions for appropriate use. Although most of the reports on rVIIa are anecdotes and case series, there is increasing data for clinical trials to help guide usage.

    Original languageEnglish (US)
    Pages (from-to)25-34
    Number of pages10
    JournalExpert Opinion on Pharmacotherapy
    Volume7
    Issue number1
    DOIs
    StatePublished - Jan 1 2006

    Keywords

    • Bleeding emergencies
    • Haemorrhage
    • Recombinant activated Factor VII
    • Transfusion

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Management of bleeding emergencies: When to use recombinant activated Factor VII'. Together they form a unique fingerprint.

  • Cite this